Kronos Bio, Inc. (KRON) Minute Stock Prediction

About:

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.

Sector:

Healthcare

Industry:

Biotechnology

Address:

Kronos Bio, Inc. 1300 South El Camino Real Suite 300 San Mateo CA 94402 United States

Website:

Home

Phone:

650-781-5200